TIMP2 and cancer: In conclusion, the present study demonstrated that CEP65 enhanced cancer cell growth, migration, invasion and metastasis, which was correlated with the decreased expression levels of TIMP-2, VTN and RAP. These oncogenic roles also indicated that CEP65 may be a potential target for cancer therapy.